ALK-Abelló — M&A Activity 2015

Dec 21, 2015

Copenhagen, 2015-12-21 09:49 CET (GLOBE NEWSWIRE) --

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that it has entered
into an agreement to divest its European veterinary business, including related
production facilities in the Netherlands. ALK’s veterinary business specialises
in the development, manufacturing and marketing of immunotherapy products for
veterinary use.

The divestment is in line with ALK’s ongoing efforts to simplify its business
structure and accelerate the rationalisation of its product portfolio. ALK’s
business strategy, as outlined in the recent Q3 interim report, is to focus
sales efforts on standardised and evidence-based products for human use, such
as the SLIT-tablet portfolio.

The agreement with the buyer – the Swedish investment company Fidelio Capital –
is final and the transaction will be effective as of 30 December 2015.

The value of the transaction is undisclosed, however, the divestment is
expected to impact ALK’s full-year guidance on free cash flow positively by DKK
40-50 million. The divestment does not materially impact ALK’s full-year
guidance for revenue and EBITDA before special items. The net gain on the sale
will be recognised as special items in the profit and loss statement.

Kempen & Co acted as exclusive M&A advisor to ALK.

ALK’s European veterinary business was expected to have revenue of
approximately DKK 30 million for 2015. The business employs 25 people.

                             ALK-Abelló A/S

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is a world leader in allergy
immunotherapy – a treatment of the underlying cause of allergy. The company has
approximately 1,900 employees with subsidiaries, production facilities and
distributors worldwide. ALK has entered into partnership agreements with MSD
(known as Merck (NYSE: MRK) in the USA and Canada), Torii, Abbott and Seqirus
(previously bioCSL) to commercialise sublingual allergy immunotherapy tablets
in North America, Japan, Russia, and Australia and New Zealand, respectively.
The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ
Copenhagen. Find more information at www.alk.net.